An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix
This article was originally published in PharmAsia News
Executive Summary
Lilly and Daiichi Sankyo's newly approved platelet inhibitor Effient (prasugrel) will be priced at an 18 percent premium to Bristol-Myers Squibb's market leader Plavix, even though Effient carries a "black box" warning for bleeding risks, the drug makers disclosed on July 15
You may also be interested in...
Daiichi Sankyo/Lilly's Prasugrel Clears FDA
WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).